News room

Lyon, France - 4 October 2006
genOway reports here the renewal of its former general service agreement with University College London (UCL), a leading research institution. The agreement covers the development of several specific mouse and rat models using the proprietary technology platform of genOway.

Researchers from UCL benefit from a personalized service aimed at developing animal models to meet their specific needs and goals and extensive consultancy services focused on developing customized and efficient model to specifications. Timelines, financial conditions and therapeutic areas of interest are not disclosed.

"With the renewal of our collaboration, University College London confirms its trust in our company and technologies. The high quality services and the customer-care policy of genOway and its staff have enabled us to establish long-term relations with leading research Institutions, such as UCL. We are very proud of this clear sign of confidence from UCL researchers and its administration" said Dr. Fraichard, CEO of genOway.

Kumamoto – Japan - September 21st, 2006
TRANSGENIC INC. and genOway S.A. announce today the signing of an agreement regarding a business tie-up on distribution and selling services related to genetically modified animals.

TRANS GENIC INC develops Knock-Out mouse models and provides information on gene functions to domestic and foreign pharmaceutical companies, universities and research institutes.

French-based genOway is a service provider dedicated to the development of transgenic mouse and rat models and offers a full range of solutions for both gene expression and gene inactivation.
genOway has developed a complete range of innovative technological solutions aimed at increasing the predictability and efficacy of target validation, drug screening and pharmacological / toxicological studies. genOway is regarded throughout Europe as a premier company providing custom services to clients.

Under the term of this agreement, genOway’s will distribute TRANSGENIC INC Knock-Out mouse models in Europe. TRANSGENIC INC will market genOway’s advanced and unique services on genetically modified mouse and rat models in Japan.

About TRANSGENIC INC
TRANS GENIC INC., based in Japan, is a tool providing company in the field of pharmaceutical and diagnostic development with its innovative technology of producing genetically engineered mice and a wide variety of antibody products. TRANS GENIC has created a large-scale knockout mice library by utilizing the 'genetrap' technology, and the gene functional information derived from the library is provided to our customers. TRANS GENIC possess the unique technology of high-affinity antibody production, using ganptransgenic mice and conduct a worldwide business with this antibody technology. In addition, TRANS GENIC INC. provide various antibody products as a research reagent. Product Lineup includes; Bio-markers for environmental hormones (Vitellogenin ELISA kit),tumor marker (Diacetylspermine ELISA Kit), antibodies related to amino acid transporters, advanced glycation end products, and still more. For more information, please visit our web site: www.transgenic.co.jp

Lyon, France - 5th July 2006
genOway reports a successful collaboration with the major bio-pharmaceutical company Boehringer Ingelheim for the development of experimental research models. This collaboration has been recently reinforced and now includes several innovative technological solutions developed by genOway to create more powerful research models.
genOway uses its technologies and expertise to develop research models for gene targets provided by Boehringer Ingelheim The resulting models are used in Boehringer Ingelheim’s drug discovery research activities, for gene function analysis as well as for the testing of novel drug candidates. Financial conditions and therapeutic areas of interest are not disclosed.
genOway's expertise and leadership in the field of transgenesis has led to the development of several cutting-edge proprietary technologies. These technologies enhance the predictability, security and robustness of the developed models. genOway has a complete range of innovative technological solutions aimed at increasing the predictability and efficacy of target validation, drug screening and pharmacological / toxicological studies.

Boehringer Ingelheim has joined genOway’s worldwide customer network, spread across 20 countries and 3 continents (Europe, Asia and North-America). More than 220 leading academic institutes & more than 30 major biopharmaceuticals companies are using genOway’s services.

"We have been proud to include Boehringer Ingelheim in our customer portfolio and we acknowledge the trust that this outstanding company has in our technology platform and service. Today, I am delighted that, following the success of our first cooperation, Boehringer Ingelheim confirms its confidence in genOway by outsourcing the generation of further research models", said Alexandre Fraichard, CEO of genOway.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and almost 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2005, Boehringer Ingelheim posted net sales of 9.5 billion euro while spending almost one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more information please visit www.boehringer-ingelheim.com

Lyon, France - June 2006
genOway announces a general agreement with the Center for Applied Medical Research (CIMA) of the University of Navarra, Pamplona, Spain. Thanks to this agreement, researchers of this renowned Institute will benefit from genOway’s expertise in transgenesis, enabling to concentrate their efforts on their core competence and speed up their research.
genOway will provide these researchers with a personalised service, aimed at developing animal models to meet their specific needs and goals, using proprietary technology platform.

CIMA is run by the Foundation for Applied Medical Research, which was established with the support of the Schools of Medicine, Science, Pharmacy and the University Hospital of the University of Navarra. The mission of this project is to promote basic, translational and clinical research in the fields of health and biomedicine. CIMA is involved in different biomedical research projects in the following divisions: Gene Therapy and Hepatology, Cardiovascular Sciences, Neurosciences and Oncology.

"genOway is proud of its collaboration with this institute and we believe that this global agreement will make our collaboration even more successful. The trust of these outstanding researchers in genOway’s expertise is a real privilege" concluded Alexandre Fraichard, CEO of genOway

"Working together with genOway, we will be able to develop our instinct of either curing diseases or, at least, getting better life conditions for patients. This international alliance is a good example of the teamwork in biomedicine", declared Francisco Errasti, General Director of CIMA.

Wilmington, MA - USA and Lyon - France, May 16 2006
Charles River Laboratories, Inc. (NYSE: CRL), a leading global provider of solutions that advance the drug discovery and development process, and genOway, the European leader in genetically modified research models, announce the establishment of a three-year North American collaboration. This strategic alliance will provide pharmaceutical, biotechnology, and academic researchers with innovative research models to better understand human diseases.

genOway holds intellectual property rights to multiple processes for the development of research models and offers a full range of solutions for both gene expression (inducible and conditional transgenic animals, knock-in models, and proprietary technologies such as Quick Knock-in^TM, Safe DNA Transgenesis^TM, etc.) and gene inactivation (conditional knock-out, gene knock-down, and proprietary solutions such as Safe Knock-out^TM, Quick RNAi^TM, etc.) in mouse and rat models. genOway is regarded throughout Europe as a premier company providing custom services to clients.

Charles River Laboratories is the market leader in model development, breeding services and model characterization, and is dedicated to providing a continuous supply of genetically specific and virally clean research models to clients around the world.

"Charles River Laboratories is delighted to expand our relationship with genOway by adding to our successful European collaboration with this North American agreement." said William Barbo, Corporate Vice President, Research Model Services. "With this collaboration, we can promote genOway’s solutions and further assist our clients in the most efficient pursuit of their research goals."

"We are thrilled to begin this exciting new collaboration with Charles River promoting our wide array of proprietary solutions and services to the North American market" said Alexandre Fraichard, CEO of genOway. "Charles River, the acknowledged market leader in this segment, shares our commitment to unsurpassed customer service, and to offering clients what they truly want and need."

Lyon, France - March 2006
genOway announces general agreements with the European Institute of Oncology (EIO) and the FIRC Institute on Molecular Oncology (IFOM). Thanks to these agreements, researchers of these renowned Institutes will benefit from genOway's expertise in transgenesis, enabling researchers in oncology to concentrate their efforts on their core competence and speed up their research.
Historically, cancer research has benefited immensely from the predictability provided by animal models for the understanding of cancer phenomena and the human reaction to pharmacological treatment. The presence of over 10 000 publications confirm this synergy (source PubMed).
Located in Milano- Italy, the EIO and IFOM are European institutions dedicated to cancer research with an international renown for the quality of their studies. These two institutions are now expanded and fused in the IFOM-IEO Campus and their scientific activities integrated.

"IEO and genOway collaboration started some years ago while we were looking for collaborative and highly professional technologists for the development of our knock-out mouse models. We have been impressed by their competence and motivation, by the solutions they found to solve our problems and by the flexibility in discussing every milestone of the project at any time. We are more than happy to continue and improve our collaboration with genOway." said Prof. Pier Giuseppe PELICCI Chairman of the Department of Experimental Oncology, IEO and Scientific Director of SEMM.

"genOway is a leading company in the field of genetically modified mouse and rat models. Its technology platform is impressive, comprising technologies classically used in trangenesis and more innovative approaches, like conditional and inducible systems. We experienced their methodology by producing few lines of transgenic animals. Design and development of the project were customized to our specific requests, there was no waiting list and the frequent reports sent by the project leader allow our researchers to follow the entire process with the possibility of a fine-tuning or eventually a re-direction of the project. We would totally recommend genOway and we are looking forward to a long relationship" said Prof. Pier Paolo DI FIORE Scientific Director of IFOM.

Theses agreements cover the development and generation of genetically modified mouse models using genOway's proprietary technology platform. genOway will provide researchers from these institutions with a personalised service, aimed at developing animal models to meet their specific needs and goals in cancer research. Since its creation, genOway has amassed significant expertise in developing specific mouse models within this therapeutical area, and from successful past collaboration with renowned researchers in this field.

"Mouse knock-out technology is an important step in cancer research, it provides relevant answers to scientific questions but it is time-consuming and difficult to set up. The Department of Experimental Oncology decided to take advantage of genOway's expertise in this field. We generated several lines of genetically modified mice together. Beside the technological success within the expected time-frame, we appreciated the frequent and fruitful exchange of ideas, the collaborative attitude of the project leaders, as well as of the consultants and directors of study. You feel that the company is truly at your service but that you can constantly re-discuss the direction of the project on the basis of the very last result you have achieved." said Dr. Luisa LANFRANCONE, group Leader at the IFOM-IEO Campus.

"The EIO and IFOM are leading research institutions dedicated to research in the field of oncology. Their highly-qualified scientists and innovative programs have led to significant advances in our understanding of the molecular basis of cancer and have contributed to the development of novel anticancer therapies. genOway has always been proud of its collaboration with these institutes and we believe that these global agreements are a confirmation of mutual confidence and will make our collaboration even more successful. The trust of these outstanding researchers in genOway's expertise is a real honour" concluded Alexandre Fraichard, CEO of genOway.

Hamburg, Germany - January 2006
Through its German subsidiary, genOway, the European market leader in transgenesis, reports the signature of a General Service Agreement with the SFB 575, a Collaborative Research Centre in Düsseldorf focused on Experimental Hepatology and funded by the German Research Council (DFG).

The non-exclusive agreements will provide researchers from the SFB 575 with a personalised service aimed at developing animal models to meet their specific needs and goals. Timelines & financial conditions have not been disclosed.

"It goes without saying that knockout technologies are an indispensible research tool in Hepatology. In this regard we started a cooperation with genOway which is highly specialized in the generation of genetically modified mice. We appreciate that genOway provides a highly professional consulting demonstrating clear-cut alternative strategies and substantiated risk analyses, which meet well our requirements. I am looking forward to a fruitful collaboration between genOway and our Collaborative Research Centre." said Prof. Dr. Dieter Häussinger, Head of the Collaborative Research Center "Experimental Hepatology", Heinrich-Heine-University, Düsseldorf.

About SFB 575
www.uni-duesseldorf.de/sfb575
The aim of this Collaborative Research Centre is to study normal liver function and the molecular mechanisms leading to clinical symptoms associated with liver injury. Based on the results the rational for new therapeutical strategies allowing more efficient treatment of liver diseases will be provided. A special focus is the investigation of intra- and intercellular communication mechanisms. This is highly topical because of increasing evidence that a dysregulation of signal transduction accounts for many diseases.